The role and contribution of leukotrienes in asthma.

[1]  R. N. Brogden,et al.  Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma. , 1998, Drugs.

[2]  T. Reiss,et al.  Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. , 1997, Thorax.

[3]  J. Kemp,et al.  Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group. , 1997, Clinical therapeutics.

[4]  S T Holgate,et al.  Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. , 1996, The Journal of allergy and clinical immunology.

[5]  E. Israel,et al.  Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. , 1996, JAMA.

[6]  J. Murray,et al.  A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. , 1996, The Journal of allergy and clinical immunology.

[7]  S. Wenzel,et al.  Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. , 1995, American journal of respiratory and critical care medicine.

[8]  T. Casale,et al.  The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. , 1995, American journal of respiratory and critical care medicine.

[9]  J. Evans,et al.  Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. , 1995, Canadian journal of physiology and pharmacology.

[10]  P. Isakson,et al.  Molecular cloning and expression of human leukotriene C4 synthase. , 1994, Advances in prostaglandin, thromboxane, and leukotriene research.

[11]  P. Sterk,et al.  The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. , 1995, The Journal of allergy and clinical immunology.

[12]  J. Drazen,et al.  Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. , 1995, Advances in prostaglandin, thromboxane, and leukotriene research.

[13]  S. Spector,et al.  Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. , 1994, American journal of respiratory and critical care medicine.

[14]  A. Williams,et al.  Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. , 1994, Thorax.

[15]  A. Williams,et al.  Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses. , 1994, Thorax.

[16]  D. Woodward,et al.  Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility in vitro , 1994, Journal of leukocyte biology.

[17]  W. Busse,et al.  The Effect of Inhibition of 5-Lipoxygenase by Zileuton in Mild-to-Moderate Asthma , 1993, Annals of Internal Medicine.

[18]  S. Dahlén,et al.  Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. , 1993, Thorax.

[19]  E. Israel,et al.  The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. , 1993, The American review of respiratory disease.

[20]  L. Cleary.  Reviews and Notes: Doctors Talking with Patients/Patients Talking with Doctors: Improving Communication in Medical Visits , 1993, Annals of Internal Medicine.

[21]  T. Takishima,et al.  The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. , 1993, The Journal of allergy and clinical immunology.

[22]  L. Smith,et al.  Inhibition of leukotriene D4‐induced bronchoconstriction in subjects with asthma: a concentration‐effect study of ICI 204,219 , 1993, Clinical pharmacology and therapeutics.

[23]  J. Kolb,et al.  Leukotriene B4 induces interleukin 5 generation from human T lymphocytes , 1993, European journal of immunology.

[24]  D. Cockcroft.  Practical issues in asthma management: correct use of inhalation devices. , 1993, Annals of allergy.

[25]  T. Haahtela,et al.  Leukotriene E4 and granulocytic infiltration into asthmatic airways , 1993, The Lancet.

[26]  P. Sterk,et al.  Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. , 1993, The American review of respiratory disease.

[27]  S. Dahlén,et al.  Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. , 1992, The American review of respiratory disease.

[28]  S. Findlay,et al.  Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. , 1992, The Journal of allergy and clinical immunology.

[29]  S. Holgate,et al.  Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. , 1992, The American review of respiratory disease.

[30]  J. Montserrat,et al.  Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients. , 1992, The American review of respiratory disease.

[31]  W. Busse,et al.  The Role of Eosinophils in the Pathophysiology of Asthma a , 1991, Annals of the New York Academy of Sciences.

[32]  R. D. Dyer,et al.  5-lipoxygenase inhibitory activity of zileuton. , 1991, The Journal of pharmacology and experimental therapeutics.

[33]  Paul H. Rubin,et al.  Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. , 1991, Thorax.

[34]  Paul H. Rubin,et al.  The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. , 1990, The New England journal of medicine.

[35]  J. Haeggström,et al.  Leukotriene A4 hydrolase: a zinc metalloenzyme. , 1990, Biochemical and biophysical research communications.

[36]  R. Dixon,et al.  Correlation between expression of 5-lipoxygenase-activating protein, 5-lipoxygenase, and cellular leukotriene synthesis. , 1990, The Journal of biological chemistry.

[37]  J. Bousquet,et al.  Eosinophilic inflammation in asthma. , 1990, The New England journal of medicine.

[38]  K. Austen,et al.  The mechanism of leukotriene B4 export from human polymorphonuclear leukocytes. , 1990, The Journal of biological chemistry.

[39]  S. Wenzel,et al.  Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. , 1990, The American review of respiratory disease.

[40]  R. Keith,et al.  The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist. , 1990, The American review of respiratory disease.

[41]  L. Smith,et al.  Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219. , 1990, The American review of respiratory disease.

[42]  R. Dixon,et al.  Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis , 1990, Nature.

[43]  W. Owen,et al.  The identification of a distinct export step following the biosynthesis of leukotriene C4 by human eosinophils. , 1989, The Journal of biological chemistry.

[44]  C. Dollery,et al.  URINARY LEUKOTRIENE E4 AFTER ANTIGEN CHALLENGE AND IN ACUTE ASTHMA AND ALLERGIC RHINITIS , 1989, The Lancet.

[45]  N. Flavahan,et al.  The eosinophil as a mediator of damage to respiratory epithelium: a model for bronchial hyperreactivity. , 1988, The Journal of allergy and clinical immunology.

[46]  D. Stevenson,et al.  Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. , 1988, The American review of respiratory disease.

[47]  M. Chan-yeung,et al.  Release of leukotrienes in patients with bronchial asthma. , 1988, The Journal of allergy and clinical immunology.

[48]  E. Chi,et al.  Propagation and characterization of human blood basophils. , 1988, International archives of allergy and applied immunology.

[49]  S. Dahlén,et al.  Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. , 1987, Science.

[50]  K. Austen,et al.  Co-culture of human lung-derived mast cells with mouse 3T3 fibroblasts: morphology and IgE-mediated release of histamine, prostaglandin D2, and leukotrienes. , 1987, Journal of immunology.

[51]  S. Suzuki,et al.  Plasma levels of leukotrienes C4 and D4 during wheezing attack in asthmatic patients. , 1987, International archives of allergy and applied immunology.

[52]  R. Clancy,et al.  Leukotriene C4 production by murine mast cells: evidence of a role for extracellular leukotriene A4. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[53]  A. Togias,et al.  Inflammatory mediators in late antigen-induced rhinitis. , 1985, The New England journal of medicine.

[54]  M. Goldyne,et al.  Arachidonic acid metabolism among human mononuclear leukocytes. Lipoxygenase-related pathways. , 1984, The Journal of biological chemistry.

[55]  N. Barnes,et al.  Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. , 1984, Thorax.

[56]  R. Naclerio,et al.  Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. , 1984, The New England journal of medicine.

[57]  K. Austen,et al.  Release of leukotrienes by human monocytes on stimulation of their phagocytic receptor for particulate activators. , 1984, Journal of immunology.

[58]  E. Corey,et al.  Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[59]  S. Dahlén,et al.  Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C4, D4, and E4. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[60]  S. Peters,et al.  Generation of leukotrienes by purified human lung mast cells. , 1982, The Journal of clinical investigation.

[61]  W. Henderson,et al.  Leukotriene generation by eosinophils , 1982, The Journal of experimental medicine.

[62]  R. Murphy,et al.  Leukotriene C: a slow-reacting substance from murine mastocytoma cells. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[63]  W. Martin,et al.  Letter: Jaundice associated with norethisterone-acetate treatment of breast cancer. , 1975, Lancet.

[64]  W E BROCKLEHURST,et al.  The release of histamine and formation of a slow‐reacting substance (SRS‐A) during anaphylactic shock , 1960, The Journal of physiology.